Brind.

BioMarin Pharmaceutical develops therapies for rare genetic disorders.

1 report, 1 independent Updated Jul 15

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

BioMarin Pharmaceutical

Keep exploring

The entities involved

BioMarin Pharmaceutical
American company
- Investors are comparing the financial performance metrics of BioMarin Pharmaceutical and Metagenomi.Sun 20:41

Related events

Applied DNA Sciences and BioMarin Pharmaceutical are identified as competing companies within the healthcare market.Sep 3

Coverage

Newest first; wire copies grouped

Jul 15StockStoryUnpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in th